Maureane Hoffman

List of Publications by Year
in descending order

193	13,225	28736 57	26792 111
papers	citations	h-index	g-index

198	198	198	9766
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A commentary on â€œA rapid, sensitive and specific assay to measure TF activity based on chromogenic determination of thrombin generationâ€. Journal of Thrombosis and Haemostasis, 2022, 20, 816-817.	1.9	0
2	Trauma-induced coagulopathy. Nature Reviews Disease Primers, 2021, 7, 30.	18.1	300
3	Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. Blood Advances, 2021, 5, 3736-3736.	2.5	6
4	Cell-Mediated Hemostasis. , 2021, , 31-41.		1
5	Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. Nature Communications, 2021, 12, 6912.	5.8	6
6	Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects. Journal of Colloid and Interface Science, 2020, 577, 406-418.	5.0	8
7	EPCR knockout: inflaming the discussion. Blood, 2020, 135, 2201-2202.	0.6	0
8	Nanosilver composite pNIPAm microgels for the development of antimicrobial plateletâ€like particles. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2020, 108, 2599-2609.	1.6	9
9	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood, 2020, 135, 755-765.	0.6	61
10	A unique protein kinaseÂCâ€dependent pathway for tissue factor downregulation in pericytes. Journal of Thrombosis and Haemostasis, 2019, 17, 670-680.	1.9	0
11	The central role of thrombin in bleeding disorders. Blood Reviews, 2019, 38, 100582.	2.8	72
12	Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Molecular Therapy, 2019, 27, 1228-1241.	3.7	52
13	Regulation of Hemostasis and Thrombosis. , 2019, , 81-89.e2.		0
14	The Tissue Factor Pathway and Wound Healing. Seminars in Thrombosis and Hemostasis, 2018, 44, 142-150.	1.5	26
15	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. International Journal of Emergency Medicine, 2018, 11, 55.	0.6	25
16	The next best thing in factor VIIa. Journal of Thrombosis and Haemostasis, 2018, 16, 1911-1913.	1.9	1
17	Biology of Coagulation and Coagulopathy in Neurologic Surgery. Neurosurgery Clinics of North America, 2018, 29, 475-483.	0.8	5
18	Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity. Journal of Thrombosis and Haemostasis, 2018, 16, 1817-1829.	1.9	10

#	Article	IF	Citations
19	Abstract 288: Nitric Oxide Mediates Active Downregulation of Tissue Factor Expression in Human Pericytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	1
20	Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. Blood, 2017, 129, 2161-2171.	0.6	40
21	Impact of Nonâ€“Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1812-1818.	1.1	15
22	Coated platelet assay: a feasible approach to a complicated science. Haemophilia, 2016, 22, e67-e70.	1.0	1
23	Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?. Haemophilia, 2016, 22, 148-151.	1.0	7
24	No association between donor age and recipient outcomes: transfusion of plasma in patients undergoing coronary artery bypass grafting surgery. Transfusion, 2016, 56, 1723-1729.	0.8	4
25	Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thrombosis Research, 2016, 146, 113-118.	0.8	75
26	An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model. Journal of Thrombosis and Haemostasis, 2016, 14, 1249-1254.	1.9	2
27	Cell-Mediated Hemostasis. , 2016, , 3-14.		2
28	Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding. Biology of Blood and Marrow Transplantation, 2015, 21, S111-S113.	2.0	2
29	Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate. Anesthesiology, 2015, 122, 353-362.	1.3	27
30	Novel oral anticoagulants and reversal agents: Considerations for clinical development. American Heart Journal, 2015, 169, 751-757.	1.2	69
31	Coagulation in Liver Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 447-454.	1.5	27
32	161: Effect of antifibrinolytic drugs on in vitro clot formation among peripartum women. American Journal of Obstetrics and Gynecology, 2015, 212, S96.	0.7	0
33	Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thrombosis and Haemostasis, 2014, 112, 189-198.	1.8	92
34	Reversing targeted oral anticoagulants. Hematology American Society of Hematology Education Program, 2014, 2014, 518-523.	0.9	4
35	A mouse bleeding model to study oral anticoagulants. Thrombosis Research, 2014, 133, S6-S8.	0.8	16
36	Hemostasis: Old System, New Players, New Directions. Thrombosis Research, 2014, 133, S1-S2.	0.8	11

#	Article	IF	Citations
37	Endothelial Protein C Receptor Is Expressed on Procoagulant Platelets and Contributes to Factor VIIa Binding and Activity. Blood, 2014, 124, 4224-4224.	0.6	1
38	Practical coagulation for the blood banker. Transfusion, 2013, 53, 1594-1602.	0.8	20
39	Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia, 2013, 19, 926-932.	1.0	8
40	Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. Journal of Thrombosis and Haemostasis, 2013, 11, 1043-1052.	1.9	23
41	Superactivated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1747-1752.	1.1	71
42	Reversal Of Dabigatran Anticoagulation By a 4-Factor Prothrombin Complex Concentrate: Correlation Between Effects On Parameters Of Thrombin Generation and Hemostatic Effect In Vivo. Blood, 2013, 122, 3643-3643.	0.6	1
43	Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity. Wound Repair and Regeneration, 2012, 20, 770-777.	1.5	19
44	Mechanisms and monitoring of bypassing agent therapy. Journal of Thrombosis and Haemostasis, 2012, 10, 1478-1485.	1.9	91
45	Hemostatic properties of the FVIIa analog NN1731. Thrombosis Research, 2012, 129, S49-S50.	0.8	0
46	The multiple roles of tissue factor in wound healing. Frontiers in Bioscience - Scholar, 2012, S4, 713-721.	0.8	6
47	Consequences of intraâ€articular bleeding in haemophilia: science to clinical practice and beyond. Haemophilia, 2012, 18, 112-119.	1.0	32
48	The clotting system â€“ a major player in wound healing. Haemophilia, 2012, 18, 11-16.	1.0	39
49	Hypothesis: Hyperhomocysteinemia is an indicator of oxidant stress. Medical Hypotheses, 2011, 77, 1088-1093.	0.8	113
50	Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin. Thrombosis Research, 2011, 127, 576-581.	0.8	15
51	Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. Journal of Thrombosis and Haemostasis, 2011, 9, 759-766.	1.9	22
52	Editorial: International normalized ratio. Journal of Neurosurgery, 2011, 114, 8.	0.9	1
53	Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. Journal of Neurosurgery, 2011, 114, 9-18.	0.9	41
54	Inflammation does not predispose to bleeding in hemophilia. Journal of Thrombosis and Haemostasis, 2010, 8, 2583-2585.	1.9	4

#	Article	IF	Citations
55	Wound healing in haemophilia â€“ breaking the vicious cycle. Haemophilia, 2010, 16, 13-18.	1.0	31
56	Heparins: Clinical Use and Laboratory Monitoring. Laboratory Medicine, 2010, 41, 621-626.	0.8	6
57	Platelet binding and activity of recombinant factor VIIa. Thrombosis Research, 2010, 125, S16-S18.	0.8	13
58	Wound healing in hemophilia B mice and low tissue factor mice. Thrombosis Research, 2010, 125, S74-S77.	0.8	24
59	Regulation of Hemostasis and Thrombosis. , 2010, , 87-95.		0
60	Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. Rna, 2009, 15, 2105-2111.	1.6	50
61	Tissue Factor in Brain Is Not Saturated With Factor VIIa. Stroke, 2009, 40, 2882-2884.	1.0	27
62	Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Experimental and Molecular Pathology, 2009, 87, 178-183.	0.9	13
63	A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. Journal of Thrombosis and Thrombolysis, 2009, 28, 132-139.	1.0	6
64	Celecoxib does not delay cutaneous wound healing in haemophilia B mice. Haemophilia, 2009, 15, 615-616.	1.0	4
65	Platelet functions beyond hemostasis. Journal of Thrombosis and Haemostasis, 2009, 7, 1759-1766.	1.9	465
66	The Coagulation Cascade in Cirrhosis. Clinics in Liver Disease, 2009, 13, 1-9.	1.0	62
67	Dysregulation of Hemostasis by Cancer. Cancer Treatment and Research, 2009, 148, 3-15.	0.2	3
68	Hypercoagulation and thrombophilia in liver disease. Journal of Thrombosis and Haemostasis, 2008, 6, 2-9.	1.9	152
69	Animal models of bleeding and tissue repair. Haemophilia, 2008, 14, 62-67.	1.0	18
70	Some things I thought I knew about tissue factor that turn out to be wrong. Thrombosis Research, 2008, 122, S73-S77.	0.8	6
71	Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. Blood, 2008, 111, 2046-2048.	0.6	31
72	FVIIa: you've come a long way, baby!. Blood, 2008, 112, 3002-3003.	0.6	4

#	Article	IF	Citations
73	Alterations of Fibrinogen Structure in Human Disease. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2008, 6, 206-211.	0.4	43
74	Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Thrombosis Research, 2007, 120, 117-126.	0.8	27
75	Coagulation 2006: A Modern View of Hemostasis. Hematology/Oncology Clinics of North America, 2007, 21, 1-11.	0.9	219
76	Fathers of modern coagulation. Thrombosis and Haemostasis, 2007, 98, 3-5.	1.8	9
77	Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 141-148.	1.9	181
78	Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. Journal of Thrombosis and Haemostasis, 2007, 5, 638-639.	1.9	24
79	Tissue factor around dermal vessels has bound factor VII in the absence of injury. Journal of Thrombosis and Haemostasis, 2007, 5, 1403-1408.	1.9	77
80	Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. Journal of Thrombosis and Haemostasis, 2007, 5, 1577-1583.	1.9	44
81	What Does It Take to Make the Perfect Clot?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 41-48.	1.1	341
82	Cutaneous wound healing is impaired in hemophilia B. Blood, 2006, 108, 3053-3060.	0.6	104
83	Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. Journal of Thrombosis and Haemostasis, 2006, 4, 2092-2093.	1.9	49
84	Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. British Journal of Haematology, 2006, 134, 314-319.	1.2	36
85	Why Are Young College Women Not Using Condoms? Their Perceived Risk, Drug Use, and Developmental Vulnerability May Provide Important Clues to Sexual Risk. Archives of Psychiatric Nursing, 2006, 20, 32-40.	0.7	82
86	Modification of Fibrinogen by Homocysteine Thiolactone Increases Resistance to Fibrinolysis:â€‰ A Potential Mechanism of the Thrombotic Tendency in Hyperhomocysteinemia. Biochemistry, 2006, 45, 2480-2487.	1.2	122
87	A Cell-Based Model of Thrombin Generation. Seminars in Thrombosis and Hemostasis, 2006, 32, 032-038.	1.5	195
88	One more way that mice and men are different. Journal of Thrombosis and Haemostasis, 2005, 3, 448-449.	1.9	5
89	High dose factor VIIa improves clot structure and stability in a model of haemophilia B. British Journal of Haematology, 2005, 131, 645-655.	1.2	127
90	Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft. Experimental and Molecular Pathology, 2005, 79, 23-32.	0.9	6

#	Article	IF	Citations
91	Rethinking the Coagulation Cascade. Japanese Journal of Thrombosis and Hemostasis, 2005, 16, 70-81.	0.1	28
92	Excess Factor VIII and Hypercoagulability. Journal of the American Board of Family Medicine, 2005, 18, 328-328.	0.8	2
93	Platelet Heterogeneity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 861-866.	1.1	89
94	Reaction of Fibrinogen with Homocysteine Thiolactone Mimics the Dysfibrinogenemia Produced by Hyperhomocysteinemia.. Blood, 2005, 106, 137-137.	0.6	1
95	The Cellular Basis of Traumatic Bleeding. Military Medicine, 2004, 169, 5-7.	0.4	25
96	Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. Journal of Thrombosis and Haemostasis, 2004, 2, 402-413.	1.9	153
97	Differences in the metabolic response to exogenous homocysteine in juvenile and adult rabbits. Journal of Nutritional Biochemistry, 2004, 15, 96-102.	1.9	7
98	Safety profile of recombinant factor VIIa. Seminars in Hematology, 2004, 41, 101-108.	1.8	170
99	A Systematic Evaluation of the Effect of Temperature on Coagulation Enzyme Activity and Platelet Function. Journal of Trauma, 2004, 56, 1221-1228.	2.3	424
100	UNDERSTANDING AND MANAGING COAGULOPATHIC BLEEDING. Shock, 2004, 21, 149.	1.0	0
101	Remodeling the Blood Coagulation Cascade. Journal of Thrombosis and Thrombolysis, 2003, 16, 17-20.	1.0	277
102	Localization of heparin cofactor II in injured human skin: a potential role in wound healing. Experimental and Molecular Pathology, 2003, 75, 109-118.	0.9	7
103	The Potential Role of Factor VIIa in Transfusion Medicine. Transfusion Alternatives in Transfusion Medicine, 2003, 5, 20-22.	0.2	0
104	Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. Journal of Thrombosis and Haemostasis, 2003, 1, 300-306.	1.9	91
105	A cell-based model of coagulation and the role of factor VIIa. Blood Reviews, 2003, 17, S1-S5.	2.8	244
106	Protease-Activated Receptor-2 Signaling Triggers Dendritic Cell Development. American Journal of Pathology, 2003, 162, 1817-1822.	1.9	74
107	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	0.4	0
108	Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood, 2003, 101, 3008-3013.	0.6	145

#	Article	IF	Citations
109	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	0.4	20
110	New Insights into the Coagulation System and Implications for New Therapeutic Options with Recombinant Factor VIIa. Current Medicinal Chemistry, 2003, 10, 797-811.	1.2	78
111	The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients. Journal of Trauma, 2003, 55, 886-891.	2.3	415
112	Expanding uses of high-dose factor VIIa. Blood, 2003, 101, 1666-1666.	0.6	1
113	Laboratory Monitoring of High-Dose Factor VIIa Therapy. Annals of Internal Medicine, 2003, 139, 791.	2.0	13
114	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	0.4	30
115	Anti-heart Antibodies in Postpericardiotomy Syndrome: Cause or Epiphenomenon?. Autoimmunity, 2002, 35, 241-245.	1.2	45
116	Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood, 2002, 100, 539-546.	0.6	49
117	Platelet-dependent action of high-dose factor VIIa. Blood, 2002, 100, 364-366.	0.6	49
118	Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood, 2002, 100, 153-158.	0.6	79
119	Analyzing fibrin clot structure using a microplate reader. Blood Coagulation and Fibrinolysis, 2002, 13, 533-539.	0.5	58
120	Platelets and Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1381-1389.	1.1	579
121	Coagulation Factor Interaction with Platelets. Thrombosis and Haemostasis, 2002, 88, 179.	1.8	14
122	Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Canadian Journal of Anaesthesia, 2002, 49, S7-14.	0.7	25
123	Exposure of Mice to Topical Bovine Thrombin Induces Systemic Autoimmunity. American Journal of Pathology, 2001, 159, 1957-1969.	1.9	53
124	Generation of Species Cross-reactive Aptamers Using â€œToggleâ€•SELEX. Molecular Therapy, 2001, 4, 567-573.	3.7	239
125	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology, 2001, 38, 6-9.	1.8	76
126	A Cell-based Model of Hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-965.	1.8	1,286

#	Article	IF	Citations
127	High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. British Journal of Haematology, 2001, 114, 114-120.	1.2	126
128	Synergism between platelets and leukocytes in inducing endothelial cell apoptosis in the cold ischemic rat liver: a Kupffer cell mediated injury. FASEB Journal, 2001, 15, 1230-1232.	0.2	104
129	A cell-based model of hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-65.	1.8	348
130	The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagulation and Fibrinolysis, 2000, 11, S3-S7.	0.5	38
131	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. American Journal of Hematology, 2000, 65, 30-34.	2.0	112
132	Inhibition of human and pig thrombin by a high-affinity nuclease-resistant RNA aptamer. Journal of the American College of Surgeons, 2000, 191, S74-S75.	0.2	0
133	Links Between the Immune and Coagulation Systems: How Do "Antiphospholipid Antibodies" Cause Thrombosis?. Immunologic Research, 2000, 22, 191-198.	1.3	14
134	The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 0373-0378.	1.5	87
135	Deencryption of Cellular Tissue Factor Is Independent of Its Cytoplasmic Domain. Biochemical and Biophysical Research Communications, 2000, 272, 332-336.	1.0	38
136	Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver. Gastroenterology, 2000, 118, 183-191.	0.6	205
137	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. , 2000, 65, 30.		5
138	Thrombin Activates Factor XI on Activated Platelets in the Absence of Factor XII. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 170-177.	1.1	169
139	Platelets from Thrombocytopenic Ponies Acutely Infected with Equine Infectious Anemia Virus Are Activated in Vivo and Hypofunctional. Virology, 1999, 259, 7-19.	1.1	28
140	Newer concepts of blood coagulation. Haemophilia, 1998, 4, 331-334.	1.0	100
141	Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.. Journal of Clinical Investigation, 1998, 102, 1994-2001.	3.9	231
142	Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thrombosis and Haemostasis, 1998, 80, 578-84.	1.8	33
143	A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagulation and Fibrinolysis, 1998, 9 Suppl 1, S15-20.	0.5	20
144	The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagulation and Fibrinolysis, 1998, 9 Suppl 1, S21-5.	0.5	1

#	Article	IF	Citations
145	From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet, The, 1997, 350, 1491-1493.	6.3	85
146	Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology, 1997, 99, 542-547.	1.2	557
147	The Effect of Active Site-inhibited Factor VIIa on Tissue Factor-initiated Coagulation Using Platelets before and after Aspirin Administration. Thrombosis and Haemostasis, 1997, 78, 1202-1208.	1.8	18
148	Variability in platelet procoagulant activity in healthy volunteers. Thrombosis Research, 1996, 81, 533-543.	0.8	68
149	Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagulation and Fibrinolysis, 1996, 7, 459-464.	0.5	100
150	Cellular Interactions in Hemostasis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 12-16.	0.5	22
151	Vascular Localization of the Heparin-binding Serpins Antithrombin, Heparin Cofactor II, and Protein C Inhibitor. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 185-191.	0.7	23
152	Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 1995, 86, 1794-1801.	0.6	153
153	The Monocyte Monolayer Assay: A Noninvasive Technique for Predicting the Severity of in Utero Hemolysis. American Journal of Perinatology, 1995, 12, 157-160.	0.6	5
154	Inhibition of Platelet-derived Growth Factor-BB-induced Fibroblast Proliferation by Plasmin-activated Î±2-Macroglobulin Is Mediated via an Î±2-Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein-dependent Mechanism. Journal of Biological Chemistry, 1995, 270, 6389-6395.	1.6	18
155	Thrombin Enhances Monocyte Secretion of Tumor Necrosis Factor and Interleukin-1 Beta By Two Distinct Mechanisms. Blood Cells, Molecules, and Diseases, 1995, 21, 156-167.	0.6	45
156	Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 1995, 86, 1794-801.	0.6	33
157	Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high- dose factor VIIa in hemophilia [see comments]. Blood, 1994, 83, 38-42.	0.6	77
158	Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: An aid in assessing marrow recovery. American Journal of Hematology, 1994, 46, 319-324.	2.0	56
159	Heparin cofactor II and thrombin. Trends in Cardiovascular Medicine, 1994, 4, 140-146.	2.3	13
160	Platelet procoagulant complex assembly in a tissue factor-initiated system. British Journal of Haematology, 1994, 88, 364-371.	1.2	99
161	Platelet activation in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 1993, 42, 182-185.	2.0	14
162	Response of blood leukocytes to thrombin receptor peptides. Journal of Leukocyte Biology, 1993, 54, 145-151.	1.5	42

#	Article	IF	Citations
163	Platelets contain releasable coagulation factor IX antigen. Blood Coagulation and Fibrinolysis, 1993, 4, 905-910.	0.5	10
164	Treatment of Immune-Mediated Thrombosis: A Pathogenically Oriented Regimen Proposal Based on Studies of 33 Patients With Antiphospholipid Syndrome. American Journal of Reproductive Immunology, 1992, 28, 293-293.	1.2	0
165	A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation. American Journal of Clinical Pathology, 1992, 98, 531-533.	0.4	46
166	Fatal necrotizing esophagitis due toPenicillium chrysogenum in a patient with acquired immunodeficiency syndrome. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 1158-1160.	1.3	50
167	Coagulation Factor IXa Binding to Activated Platelets and Platelet-Derived Microparticles: A Flow Cytometric Study. Thrombosis and Haemostasis, 1992, 68, 074-078.	1.8	81
168	Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thrombosis and Haemostasis, 1992, 68, 74-8.	1.8	13
169	The effects of heparin cofactor II-derived chemotaxins on neutrophil actin conformation and cyclic AMP levels. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1095, 78-82.	1.9	4
170	Antibodyâ€€Coated Erythrocytes Induce Secretion of Tumor Necrosis Factor by Human Monocytes: A Mechanism for the Production of Fever by Incompatible Transfusions. Vox Sanguinis, 1991, 60, 184-187.	0.7	17
171	The Effect of Alpha2Macroglobulin-Proteinase Complexes on Macrophage IA Expression in Vivo. Immunological Investigations, 1991, 20, 33-43.	1.0	1
172	Leukocyte chemoattractant peptides from the serpin heparin cofactor II.. Journal of Biological Chemistry, 1991, 266, 704-709.	1.6	42
173	Leukocyte chemoattractant peptides from the serpin heparin cofactor II. Journal of Biological Chemistry, 1991, 266, 704-9.	1.6	27
174	Variability in the Fibrinogen and Von Willebrand Factor Content of Cryoprecipitate: Implications for Reducing Donor Exposure. American Journal of Clinical Pathology, 1990, 93, 694-697.	0.4	22
175	PDGF-stimulated fibroblast proliferation is enhanced synergistically by receptor-recognized ?2-Macroglobulin. Journal of Cellular Physiology, 1990, 145, 1-8.	2.0	60
176	Characteristics of the Chemotactic Activity of Heparin Cofactor II Proteolysis Products. Journal of Leukocyte Biology, 1990, 48, 156-162.	1.5	20
177	Production of chemotactic peptides by neutrophil degradation of heparin cofactor II. Thrombosis Research, 1990, 57, 77-85.	0.8	7
178	Effect of interferon-Î³ and human Î±2-macroglobulin on peritoneal macrophage morphology and Ia antigen expression. Biochimica Et Biophysica Acta - Molecular Cell Research, 1990, 1051, 166-173.	1.9	6
179	Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood, 1989, 73, 1682-1685.	0.6	30
180	Comparison of the effects of IL-1Î± and TNF-Î± on phagocyte accumulation and murine antibacterial immunity. Cellular Immunology, 1989, 123, 9-22.	1.4	21

#	Article	IF	Citations
181	Alpha-Macroglobulin Secreted by Alveolar Macrophages Serves as a Binding Protein for a Macrophage-derived Homologue of Platelet-derived Growth Factor. American Journal of Respiratory Cell and Molecular Biology, 1989, 1, 171-179.	1.4	29
182	Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood, 1989, 73, 1682-1685.	0.6	4
183	Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood, 1989, 73, 1682-5.	0.6	5
184	Î± 2Macroglobulin-proteinase complexes stimulate prostaglandin E2 synthesis by peritoneal macrophages. Agents and Actions, 1988, 25, 360-367.	0.7	15
185	Reduced trypsin-binding capacity of Î±2-macroglobulin in the peritoneal fluid of women with endometriosis: possible relevance to alterations in macrophase function**Supported by the Career Development Program of the Veterans Administration (M.H.); the Josiah Charles Trent Foundation (A.F.H.); the Veterans Administration, research grant P01-A123308 from the National Institutes of Health and the James Swiger Hematology Research Fund (J.B.W.).. Fertility and Sterility, 1988, 50, 39-47.	0.5	6
186	The Effect of Fibrin Polymerization Inhibitors on Quantitative Measurements of Plasma Fibrinogen. American Journal of Clinical Pathology, 1987, 88, 490-493.	0.4	10
187	Tumor Necrosis Factor-Î± Induces Increased Hydrogen Peroxide Production and Fc Receptor Expression, but Not Increased Ia Antigen Expression by Peritoneal Macrophages. Journal of Leukocyte Biology, 1987, 42, 704-707.	1.5	75
188	The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and Î±1-proteinase inhibitor. Thrombosis Research, 1986, 41, 707-715.	0.8	11
189	Î±2-macroglobulin â€˜fastâ€™ forms inhibit superoxide production by activated macrophages. Biochimica Et Biophysica Acta - General Subjects, 1983, 760, 421-423.	1.1	54
190	Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages. Biochemical Pharmacology, 1982, 31, 775-780.	2.0	18
191	Adaptation to hyperoxia in the neonatal rat: Kinetic parameters of the oxygen-mediated induction of lung superoxide dismutases, catalase and glutathione peroxidase. Toxicology, 1980, 16, 215-225.	2.0	51
192	Production of superoxide anion by an nadph-oxidase from rat pulmonary macrophages. FEBS Letters, 1980, 121, 352-354.	1.3	16
193	Changes in Oxygen Consumption and Phagocytosis in Rat Pulmonary Macrophages Related to Animal Maturation. Experimental Lung Research, 1980, 1, 313-322.	0.5	2